Clinical trial
Long-term, Open-label Follow-up Treatment of Patients With Atrial Fibrillation Who Have Been Previously Treated With BIBR 1048 in the PETRO Trial (Trial 1160.20 - NCT01227629). (PETRO Extension Trial: PETRO-Ex)
NCT00157248 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-term, Open-label Follow-up Treatment of Patients With Atrial Fibrillation Who Have Been Previously Treated With BIBR 1048 in the PETRO Trial (Trial 1160.20 - NCT01227629). (PETRO Extension Trial: PETRO-Ex)
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 31, 2003
- Completion date
- Not reported
- Enrollment
- 361 (actual)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.